sma news today published interesting article perhaps another opportunity living kennedy disease gene therapy neurodegenerative diseases granted priority patent status patent application gene therapy candidate developed vybion treatment huntington disease spinal muscular atrophy sma neurodegenerative diseases granted track one status patent trademark office uspto patent application covers treatment composition methods use track one designation gives application priority review allowing get final decision within year track one fewer requirements need pre examination search application vybion pleased receive track status anticipates rapid review allowance vybion ceo lee henderson said press release gene therapy specifically designed target neurologic diseases caused polyq expansions resulting mutant proteins accumulate motor neurons subsequently lead cellular degeneration gene therapy aims detect target toxic sequence promoting degradation thereby preventing accumulation neuronal cells considered potential therapeutic strategy neurodegenerative diseases similar biological features spinal cerebellar ataxia alzheimer disease spinal bulbar muscular atrophy sbma however treatment far fully developed huntington according vybion drug pipeline studies required validate effectiveness safety neurodegenerative conditions read entire article click title want read actual study follow link journal neurodegnerative diseases